[1]
|
Sung, H., Ferlay, J., Siegel, R.L., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249.
https://doi.org/10.3322/caac.21660
|
[2]
|
Mirhadi, S., Tam, S., Li, Q., et al. (2022) Integrative Analysis of Non-Small Cell Lung Cancer Patient-Derived Xenografts Identifies Distinct Proteotypes Associated with Patient Out-comes. Nature Communications, 13, 1811-1827.
https://doi.org/10.1038/s41467-022-29444-9
|
[3]
|
Bie, F., Tian, H., Sun, N., et al. (2022) Research Progress of Anti-PD-1/PD-L1 Immunotherapy Related Mechanisms and Predictive Biomarkers in NSCLC. Frontiers in Oncology, 12, 769124-132.
https://doi.org/10.3389/fonc.2022.769124
|
[4]
|
Hui, E. (2019) Immune checkpoint inhibitors. Journal of Cell Biol-ogy, 218, 740-741.
https://doi.org/10.1083/jcb.201810035
|
[5]
|
Jiang, Y., Chen, M., Nie, H., et al. (2019) PD-1 and PD-L1 in Cancer Immunotherapy: Clinical Implications and Future Considerations. Human Vaccines & Immunotherapeutics, 15, 1111-1122.
https://doi.org/10.1080/21645515.2019.1571892
|
[6]
|
Yi, M., Zheng, X., Niu, M., et al. (2022) Combination Strategies with PD-1/PD-L1 Blockade: Current Advances and Future Directions. Molecular Cancer, 21, 28-55. https://doi.org/10.1186/s12943-021-01489-2
|
[7]
|
Reck, M., Rodríguez-Abreu, D., Robinson, A.G., et al. (2021) Five-Year Outcomes with Pembrolizumab versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer with PD-L1 Tumor Proportion Score ≥ 50. Journal of Clinical Oncology, 39, 2339-2349. https://doi.org/10.1200/JCO.21.00174
|
[8]
|
Mok, T., Wu, Y.L., Kudaba, I., et al. (2019) Pembrolizumab versus Chemotherapy for Previously Untreated, PD-L1- Expressing, Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (KEYNOTE-042): A Randomised, Open- Label, Controlled, Phase 3 Trial. The Lancet, 393, 1819-1830. https://doi.org/10.1016/S0140-6736(18)32409-7
|
[9]
|
Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., et al. (2018) Pembrolizumab plus Chemotherapy in Metastatic Non- Small-Cell Lung Cancer. The New England Journal of Medicine, 378, 2078-2092.
https://doi.org/10.1056/NEJMoa1801005
|
[10]
|
Socinski, M.A., Jotte, R.M., Cappuzzo, F., et al. (2018) Atezoli-zumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. The New England Journal of Medicine, 378, 2288-2301. https://doi.org/10.1056/NEJMoa1716948
|
[11]
|
Paz-Ares, L., Luft, A., Vicente, D., et al. (2018) Pem-brolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. The New England Journal of Medicine, 379, 2040-2051. https://doi.org/10.1056/NEJMoa1810865
|
[12]
|
Cascone, T., William, W.J., Weissferdt, A., et al. (2021) Neoadjuvant Nivolumab or Nivolumab plus Ipilimumab in Operable Non-Small Cell Lung Cancer: The Phase 2 Ran-domized NEOSTAR Trial. Nature Medicine, 27, 504-514.
https://doi.org/10.1038/s41591-020-01224-2
|
[13]
|
Shu, C.A., Gainor, J.F., Awad, M.M., et al. (2020) Neoadjuvant Atezolizumab and Chemotherapy in Patients with Resectable Non-Small-Cell Lung Cancer: An Open-Label, Multicentre, Single-Arm, Phase 2 Trial. The Lancet Oncology, 21, 786-795. https://doi.org/10.1016/S1470-2045(20)30140-6
|
[14]
|
Kumar, U.S., Natarajan, A., Massoud, T.F., et al. (2022) FN3 Linked Nanobubbles as a Targeted Contrast Agent for US Imaging of Cancer-Associated Human PD-L1. Journal of Controlled Release, 346, 317-327.
https://doi.org/10.1016/j.jconrel.2022.04.030
|
[15]
|
Mei, J., Xu, J., Yang, X., et al. (2021) A Comparability Study of Natural and Deglycosylated PD-L1 Levels in Lung Cancer: Evidence from Immunohistochemical Analysis. Molecular Cancer, 20, 11-18.
https://doi.org/10.1186/s12943-020-01304-4
|
[16]
|
Hellmann, M.D., Ciuleanu, T.E., Pluzanski, A., et al. (2018) Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden. The New England Journal of Medi-cine, 378, 2093-2104.
https://doi.org/10.1056/NEJMoa1801946
|
[17]
|
Carbone, D.P., Reck, M., Paz-Ares, L., et al. (2017) First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer. The New England Journal of Medicine, 376, 2415-2426. https://doi.org/10.1056/NEJMoa1613493
|
[18]
|
Kim, E.S., Velcheti, V., Mekhail, T., et al. (2022) Blood-Based Tumor Mutational Burden as a Biomarker for Atezolizumab in Non-Small Cell Lung Cancer: The Phase 2 B-F1RST Trial. Nature Medicine, 28, 939-945.
https://doi.org/10.1038/s41591-022-01754-x
|
[19]
|
Brambilla, E., Le Teuff, G., Marguet, S., et al. (2016) Prognostic Effect of Tumor Lymphocytic Infiltration in Resectable Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 34, 1223-1230.
https://doi.org/10.1200/JCO.2015.63.0970
|
[20]
|
Francini, E., Ou, F.S., Lazzi, S., et al. (2021) The Prognostic Value of CD3+ Tumor-Infiltrating Lymphocytes for Stage II Colon Cancer According to Use of Adjuvant Chemotherapy: A Large Single-Institution Cohort Study. Translational Oncology, 14, Article ID: 100973. https://doi.org/10.1016/j.tranon.2020.100973
|
[21]
|
Chen, B., Li, H., Liu, C., et al. (2020) Prognostic Value of the Common Tumour-Infiltrating Lymphocyte Subtypes for Patients with Non-Small Cell Lung Cancer: A Meta-Analysis. PLOS ONE, 15, e0242173.
https://doi.org/10.1371/journal.pone.0242173
|
[22]
|
Fumet, J.D., Richard, C., Ledys, F., et al. (2018) Prognostic and Predictive Role of CD8 and PD-L1 Determination in Lung Tumor Tissue of Patients under Anti-PD-1 Therapy. British Journal of Cancer, 119, 950-960.
https://doi.org/10.1038/s41416-018-0220-9
|
[23]
|
Mazzaschi, G., Madeddu, D., Falco, A., et al. (2018) Low PD-1 Expression in Cytotoxic CD8+ Tumor-Infiltrating Lymphocytes Confers an Immune-Privileged Tissue Microenvironment in NSCLC with a Prognostic and Predictive Value. Clinical Cancer Research, 24, 407-419. https://doi.org/10.1158/1078-0432.CCR-17-2156
|
[24]
|
Yeong, J., Suteja, L., Simoni, Y., et al. (2021) Intratumoral CD39+CD8+ T Cells Predict Response to Programmed Cell Death Protein-1 or Programmed Death Ligand-1 Blockade in Patients with NSCLC. Journal of Thoracic Oncology, 16, 1349-1358. https://doi.org/10.1016/j.jtho.2021.04.016
|
[25]
|
Sanmamed, M.F., Nie, X., Desai, S.S., et al. (2021) A Burned-Out CD8+ T-Cell Subset Expands in the Tumor Microenvironment and Curbs Cancer Immunotherapy. Cancer Discovery, 11, 1700-1715.
https://doi.org/10.1158/2159-8290.CD-20-0962
|
[26]
|
Teng, M.W., Ngiow, S.F., Ribas, A., et al. (2015) Classify-ing Cancers Based on T-Cell Infiltration and PD-L1. Cancer Research, 75, 2139-2145. https://doi.org/10.1158/0008-5472.CAN-15-0255
|
[27]
|
Kudo, M. (2020) A New Era in Systemic Therapy for Hepatocellular Carcinoma: Atezolizumab plus Bevacizumab Combination Therapy. Liver Cancer, 9, 119-137. https://doi.org/10.1159/000505189
|
[28]
|
Manabe, K., Yamasaki, O., Nakagawa, Y., et al. (2021) Multifunctionality of CD8+ T Cells and PD-L1 Expression as a Biomarker of Anti-PD-1 Antibody Efficacy in Advanced Melanoma. The Journal of Dermatology, 48, 1186-1192.
https://doi.org/10.1111/1346-8138.15904
|
[29]
|
Zhang, L., Chen, Y., Wang, H., et al. (2021) Massive PD-L1 and CD8 Double Positive TILs Characterize an Immunosuppressive Microenvironment with High Mutational Burden in Lung Cancer. The Journal for ImmunoTherapy of Cancer, 9, e002356. https://doi.org/10.1136/jitc-2021-002356
|
[30]
|
Xiang, X., Wang, J., Lu, D., et al. (2021) Targeting Tu-mor-Associated Macrophages to Synergize Tumor Immunotherapy. Signal Transduction and Targeted Therapy, 6, 75-86. https://doi.org/10.1038/s41392-021-00484-9
|
[31]
|
乔艳艳, 傅恩清. 肿瘤相关巨噬细胞在肺癌中的研究进展[J]. 中国肺癌杂志, 2022, 25(1): 34-39.
|
[32]
|
Romano, E., Kusio-Kobialka, M., Foukas, P.G., et al. (2015) Ipili-mumab-Dependent Cell-Mediated Cytotoxicity of Regulatory T Cells ex Vivo by Nonclassical Monocytes in Melanoma Patients. Proceedings of the National Academy of Sciences of the United States of America, 112, 6140-6145. https://doi.org/10.1073/pnas.1417320112
|
[33]
|
Liu, Y., Zugazagoitia, J., Ahmed, F.S., et al. (2020) Immune Cell PD-L1 Colocalizes with Macrophages and Is Associated with Outcome in PD-1 Pathway Blockade Therapy. Clinical Cancer Research, 26, 970-977.
https://doi.org/10.1158/1078-0432.CCR-19-1040
|
[34]
|
Ben-Shmuel, A., Biber, G. and Barda-Saad, M. (2020) Un-leashing Natural Killer Cells in the Tumor Microenvironment— The Next Generation of Immunotherapy? Frontiers in Immunology, 11, 275-297.
https://doi.org/10.3389/fimmu.2020.00275
|
[35]
|
Riaz, N., Havel, J.J., Makarov, V., et al. (2017) Tumor and Mi-croenvironment Evolution during Immunotherapy with Nivolumab. Cell, 171, 934-949. https://doi.org/10.1016/j.cell.2017.09.028
|
[36]
|
Le, D.T., Uram, J.N., Wang, H., et al. (2015) PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. The New England Journal of Medicine, 372, 2509-2520. https://doi.org/10.1056/NEJMoa1500596
|
[37]
|
Fanale, D., Corsini, L.R., Scalia, R., et al. (2022) Can the Tu-mor-Agnostic Evaluation of MSI/MMR Status Be the Common Denominator for the Immunotherapy Treatment of Pa-tients with Several Solid Tumors? Critical Reviews in Oncology/Hematology, 170, Article ID: 103597. https://doi.org/10.1016/j.critrevonc.2022.103597
|
[38]
|
Lenz, H.J., Van Cutsem, E., Luisa, L.M., et al. (2022) First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Meta-static Colorectal Cancer: The Phase II CheckMate 142 Study. Journal of Clinical Oncology, 40, 161-170. https://doi.org/10.1200/JCO.21.01015
|
[39]
|
Diaz, L.J., Shiu, K.K., Kim, T.W., et al. (2022) Pembrolizumab versus Chemotherapy for Microsatellite Instability-High or Mismatch Repair-Deficient Metastatic Colorectal Cancer (KEYNOTE-177): Final Analysis of a Randomised, Open-Label, Phase 3 Study. The Lancet Oncology, 23, 659-670.
https://doi.org/10.1016/S1470-2045(22)00197-8
|
[40]
|
丁培荣. 微卫星高度不稳定结直肠癌的免疫治疗[J]. 中华胃肠外科杂志, 2022, 25(3): 199-204.
|
[41]
|
Sepich-Poore G D, Zitvogel L, Straussman R, et al. (2021) The Micro-biome and Human Cancer. Science, 371, 4552-4586.
https://doi.org/10.1126/science.abc4552
|
[42]
|
Hopkins, A.M., Badaoui, S., Kichenadasse, G., et al. (2022) Efficacy of Atezolizumab in Patients with Advanced NSCLC Receiving Concomitant Antibiotic or Proton Pump Inhibitor Treat-ment: Pooled Analysis of Five Randomized Control Trials. Journal of Thoracic Oncology, 17, 758-767. https://doi.org/10.1016/j.jtho.2022.02.003
|
[43]
|
Derosa, L., Routy, B., Thomas, A.M., et al. (2022) Intestinal Ak-kermansia muciniphila Predicts Clinical Response to PD-1 Blockade in Patients with Advanced Non-Small-Cell Lung Cancer. Nature Medicine, 28, 315-324.
https://doi.org/10.1038/s41591-021-01655-5
|
[44]
|
Lee, S.H., Cho, S.Y., Yoon, Y., et al. (2021) Bifidobacterium bifidum Strains Synergize with Immune Checkpoint Inhibitors to Reduce Tumour Burden in Mice. Nature Microbiology, 6, 277-288.
https://doi.org/10.1038/s41564-020-00831-6
|
[45]
|
Hakozaki, T., Richard, C., Elkrief, A., et al. (2020) The Gut Mi-crobiome Associates with Immune Checkpoint Inhibition Outcomes in Patients with Advanced Non-Small Cell Lung Cancer. Cancer Immunology Research, 8, 1243-1250.
https://doi.org/10.1158/2326-6066.CIR-20-0196
|